By Andrea Anderson

WASHINGTON, DC (GenomeWeb News) – The Cancer Genome Atlas (TCGA) plans to completely characterize 200 samples from each of 10 tumor types over the next two years and 20 tumor types within five years, attendees at the American Association for Cancer Research annual meeting heard here yesterday.

As in the pilot stage of the project, Phase II of TCGA will involve sequence, SNP, and copy number analyses for each cancer type, as well as studies of expression, methylation, and small RNA profiles.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.

Sep
27
Sponsored by
Philips Genomics

This webinar will present an in-depth look at how Memorial Sloan Kettering Cancer Center has developed and implemented a next-generation sequencing panel for mutational tumor profiling of advanced cancer patients.

Sep
28
Sponsored by
Fabric Genomics

This webinar will discuss the critical role that software can play for clinical labs looking to establish comprehensive genomic testing programs.